Abstracts tagged "Benefits"

Abstract Number: 1489 • ACR/ARP Annual Meeting 2019
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Tim Jansen¹, Eric-Jan Kroot ², Arie van Vliet ³, Jan Pander ⁴ and Marijn Vis ⁵, ¹Viecuri MC, Venlo, Netherlands, ²Elkerliek, Helmond, Netherlands, ³Celgene, Utretcht, Netherlands, ⁴Celgene, Utrecht, Netherlands, ⁵ErasmusMC, Rotterdam, Netherlands
Background/Purpose: Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited number of active joints have a high likelihood of achieving…
Abstract Number: 1535 • ACR/ARHP Annual Meeting 2018
Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits
Genevieve Hickey¹, Caprice Hunt¹, Molly Keebler², Delesha M. Carpenter³, Elizabeth (Blair) Solow⁴, Valerie Reyna⁵, W. Benjamin Nowell⁶, Cynthia Edmonds¹, Kimberlee O'Neill¹ and Susan J. Blalock¹, ¹Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Center for BrainHealth, University of Texas Dallas, Dallas, TX, ³Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, NC, ⁴UT Southwestern Rheumatology, Dallas, TX, ⁵Cornell University, Ithica, NY, ⁶Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: Guidelines for the treatment of rheumatoid arthritis (RA) underscore the importance of an early and targeted approach to control inflammation. However, patients are often…
Abstract Number: 2809 • ACR/ARHP Annual Meeting 2018
Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
Serge Ferrari¹, E. Michael Lewiecki², Peter W. Butler³, David L Kendler⁴, Nicola Napoli⁵, Shuang Huang³, Daria B Crittenden³, Nicola Pannacciulli³, E.S. Siris⁶ and Neil Binkley⁷, ¹Geneva University Hospital, Geneva, Switzerland, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Amgen Inc., Thousand Oaks, CA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Columbia University Medical Center, New York, NY, ⁷University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI
Background/Purpose: Osteoporosis is a chronic disease, yet skeletal safety events—atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ)—remain a concern with long-term treatment. Ten…
Abstract Number: 1707 • ACR/ARHP Annual Meeting 2016
Ustekinumab and the Comparative Risk for Acute Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis
Fenglong Xie¹, Lang Chen¹, Huifeng Yun² and Jeffrey R. Curtis³, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ustekinumab (UST), an anti IL12/IL23 monoclonal antibody, is a relatively new biologic used for the treatment of psoriasis (PSO) and psoriatic arthritis (PSA). Its…
Abstract Number: 2505 • ACR/ARHP Annual Meeting 2016
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 505 • ACR/ARHP Annual Meeting 2014
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…
Abstract Number: 1425 • ACR/ARHP Annual Meeting 2013
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Arthur Kavanaugh¹, Susan J. Lee^2,3, Daniel H. Solomon⁴, Jeffrey D. Greenberg⁵, Joel M. Kremer⁶, Lilian Soto⁷, Carol J. Etzel^8,9 and George W. Reed¹⁰, ¹University of California, San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³San Diego Veterans Affairs Medical Center, San Diego, CA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁵NYU Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷University of California San Diego, San Diego, CA, ⁸Department of Epidemiology, UT MD Anderson, Houston, TX, ⁹PO Box 786, Corrona, LLC., Southborough, MA, ¹⁰Corrona, LLC., Southborough, MA
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…